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Background: The prognostic significance of age in colorectal cancer remains controversial. Our purpose was to
determine the impact of age at diagnosis on cause- specific survival and overall survival in patients with colorectal
cancer.
Methods: Using Surveillance, Epidemiology, and End Results (SEER) population-based data, we identified 226,430
patients with colorectal cancer diagnosed between 1996 and 2005. Patients were separated into 10-year age
groups. Five-year cancer cause-specific survival and overall survival data were obtained. Kaplan-Meier methods were
adopted and multivariable Cox regression models were built for the analysis of long-term survival outcomes and
risk factors.
Results: In the operated group, those aged 51–60 had the best prognosis with 5-year cause-specific survival of 72.3%
and 5-year overall survival of 68.3%.In the non-operated group, those of young age 15–30 had the best prognosis with
5-year cause-specific survival of 21.2% and 5-year overall survival of 18.2%, and there was continued worsening in cause-
specific survival and overall survival with increasing age, except for a small increase in the 51–60 age group (P < 0.001).
Multivariable analysis demonstrated a statistically significant disadvantage in cause-specific survival in patients older than
60 (P < 0.001), but the difference between the 51–60 age group and the younger age group (15–30, 31–40, 41–50)
wasn’t statistically significant (P > 0.05) in both operated and non-operated patients.
Conclusions: There was no apparent difference in survival in colorectal cancer patients 60 and younger, but in those
older than 60 years, there was worsening in overall survival and cause-specific survival in both operated and non-
operated patients.
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Colorectal cancer (CRC) is one of the most common
malignancies and is ranked as the second leading cause
of cancer-related deaths in the USA [1]. Median age at
diagnosis is 69 years, and patients younger than 50 years
represent approximately 10% of CRC [1-3]. The inci-
dence of CRC has been increasing in younger patients
over time [4]. While age plays a significant role in some
cancers, such as thyroid, the notion that age is a signifi-
cant prognostic factor in CRC has been controversial.* Correspondence: yxyxlc@aliyun.com; tongjiandong@csco.org.cn
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unless otherwise stated.For example, various studies have reported poorer prog-
nosis among young patients with CRC [5-7], while other
authors have demonstrated that young patients with
CRC surgically treated appeared to have a higher cancer
specific survival (CSS) rate than elderly ones [8-10].
Some studies showed more advanced stages in old
patients [11] whereas others did not [12]. Furthermore,
the current definition of young or elderly patients with
CRC remains controversial.
Although the majority of studies in the literature used
the cutoff age of 40 to denote young patients with CRC
[5,9,13-15], some other studies have used cutoff age of
30 [15,16], 25 [17] or others [18-20]. The definition of
an elderly patient has included cutoffs ages of 60 [21],
70 [22], 75 [23] and even 80 years [24,25]. The majority
of studies was individually limited by surgical resection,is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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on patients who were not surgically treated.
Our primary objective in this study was to determine
the impact of age on the primary outcomes of CSS and
overall survival (OS) among patients with CRC treated
or not treated with surgical resection using data from
SEER (Surveillance, Epidemiology, and End Results)
database. Our secondary objectives was to determine
whether there were differences in clinicopathological
characteristics at the time of diagnosis for the various
age groups.
Methods
We used data from the SEER cancer registry to conduct
this study. SEER, a population-based registry sponsored
by the National Cancer Institute, collects information on
cancer incidence and survival from 17 population-based
cancer registries, including approximately 28% of the U.S.
population [26]. SEER data contain no identifiers and are
publicly available for studies on cancer-based epidemi-
ology and health policy. The National Cancer Institute’s
SEER*Stat software (Surveillance Research Program,
National Cancer Institute SEER*Stat software, www.
seer.cancer.gov/seerstat) (Version 8.1.2) was used to
identify patients whose pathological diagnosis was inva-
sive CRC (C18.0-20.9) between 1996 and 2005. Only
patients of adult age (≥15 years) were included. Histology
types were limited to adenocarcinoma (8150/3, 8210/3,
8261/3, 8263/3), mucinous adenocarcinoma (8480/3),
and signet ring cell carcinoma (8490/3). Patients were
excluded if they had in situ staging.
Ethics statement
This study was in compliance with the Helsinki Dec-
laration. An independent ethics committee/institu-
tional review board at Yangzhou University approved
our study. Data released from the SEER database do
not require informed patient consent because they
contain no identifiers and were publicly available. We
have got permission to access the research data file in
the SEER program by National Cancer Institute, USA
and the reference number was 11756-Nov2013.
Statistical analysis
Our use of the term “age” refers to “age at diagnosis”
when not otherwise specified. Aside from ages 15–30
which were grouped together for a relatively small num-
ber of patients, other patients were stratified into 10-
year age groups. Rather than dichotomizing patients as
younger versus older, use of ten-year age groups allowed
for a more detailed analysis of treatment by age. The pri-
mary endpoint of this study was CRC–cause-specific
survival (CCSS) which was calculated from the date of
diagnosis to the date of cancer-specific death and wasshown as “SEER cause-specific survival” in SEER data-
base. Overall survival (OS) was calculated from the date
of diagnosis to the date of death, which was indicated as
“Vital Status” in the SEER database. Age, sex, race, TNM
stage, tumor location, tumor grade, histological type,
CCSS and, OS were assessed. Adjuvant chemotherapy
was not evaluated, as the SEER registry does not include
this information. TNM classification was restaged accord-
ing to the criteria described in the American Joint Com-
mittee on Cancer (AJCC) Cancer Staging Manual (7th
edition, 2010).
Chi-square (χ2) tests were used for tests of independ-
ent parameters. Survival curves were generated using
Kaplan-Meier estimates, and differences between curves
were analyzed using the log-rank test. Multivariable Cox
regression models were built for analysis of risk factors
of survival outcomes. Exact 95% confidence intervals
(CIs) for proportions were calculated. The nonlinear
effect of age on the hazard ratio (HR) of CRC-specific
mortality was assessed using quintic polynomial regres-
sion, with the R2 reported. All statistical analysis was
done using the statistical software package SPSS for
Windows, version 17 (SPSS Inc., Chicago, IL, USA).
Statistical significance was set at two-sided P < 0.05.
Results
Clinicopathological differences between age groups
We identified 226,430 eligible patients with CRC in the
SEER database during the 10-year study period (between
1996 and 2005). In the 15–30 age group, there were
1,181 patients; 5,333 in the 31–40 age group; 18,727 in
the 41–50 age group; 39,125 in the 51–60 age group;
53,540 in the 61–70 age group; 64,642 in the 71–80 age
group and 43,882 in the 80+ age group. The proportion
of colon cancer patients and Caucasian patients grad-
ually increased with age. Our 51–60, 61–70 and 71–
80 age groups had a significantly larger proportion of
grade I/II tumors at presentation (P < 0.001), as well
as a significantly higher proportion of adenocarcin-
oma (P < 0.001), The proportions of patients receiving
surgical resection was roughly same for the 15–30 to
71–80 age group with proportions varying from
90.2% to 91.4%, but it decreased to 84.1% for 80+ age
group. The proportions of patients with stage I/II
CRC gradually increased from 27.6% in the 15–30
age group to 46.0% in the 71–80 age group, but it
decreased to 44.9% in the 80+ age group, which had
highest proportion of unstaged patients (P < 0.05)
(Table 1).
Impact of age on survival outcomes in patients with CRC
We observed two significant findings. First, in the oper-
ated group, those aged 51–60 had the best prognosis
with a 5-year CCSS of 72.3% and a 5-year OS of 68.3%.
Table 1 Characteristics of patients from SEER database by age
15-30 31-40 41-50 51-60 61-70 71-80 >80 P value
Characteristic (n = 1181) (n = 5333) (n = 18727) (n = 39125) (n = 53540) (n = 64642) (n = 43882)
Site <0.001
Colon 878 3854 13619 29335 42067 52767 36839
% 76.1% 73.6% 73.8% 76.1% 79.8% 83.0% 85.6%
Rectum 276 1382 4823 9194 10625 10772 6205
% 23.9% 26.4% 26.2% 23.9% 20.2% 17.0% 14.4%
Sex
Male 622 2881 10188 22876 30443 32157 16326 <0.001
% 52.7% 54.0% 54.4% 58.5% 56.9% 49.7% 37.2%
Female 559 2452 8539 16249 23097 32485 27556
% 47.3% 46.0% 45.6% 41.5% 43.1% 50.3% 62.8%
Surgery Resection <0.001
Yes 1073 4874 17025 35729 48909 58248 36890
% 90.9% 91.4% 90.9% 91.3% 91.4% 90.2% 84.1%
No 98 416 1594 3150 4318 6017 6647
% 8.3% 7.8% 8.5% 8.1% 8.1% 9.3% 15.2%
Unknown 10 43 105 243 292 347 316
% 0.8% 0.8% 0.6% 0.6% 0.5% 0.5% 0.7%
Grade <0.001
I/II 687 3555 13196 28331 39003 46869 30960
% 58.2% 66.7% 70.5% 72.4% 72.8% 72.5% 70.6%
III/IV 358 1232 3589 6649 9212 11727 8526
% 30.3% 23.1% 19.2% 17.0% 17.2% 18.1% 19.4%
Unknown 136 546 1942 4145 5325 6046 4396
% 11.5% 10.2% 10.4% 10.6% 9.9% 9.4% 10.0%
Race <0.001
Caucasian 865 3943 14062 30358 42785 54227 38195
% 73.2% 73.9% 75.1% 77.6% 79.9% 83.9% 87.0%
African American 158 726 2689 5190 6144 5550 3101
% 13.4% 13.6% 14.4% 13.3% 11.5% 8.6% 7.1%
Others* 153 637 1864 3361 4358 4604 2458
% 13.0% 11.9% 10.0% 8.6% 8.1% 7.1% 5.6%
Unknown 5 27 112 216 253 261 128
% 0.4% 0.5% 0.6% 0.6% 0.5% 0.4% 0.3%
Histological Type <0.001
Adenocarcinoma 833 4363 16225 34740 47536 56905 38431
% 72.2% 82.5% 86.9% 89.0% 88.9% 88.1% 87.7%
Mucinous/Signet-ring cancer 320 927 2440 4308 5927 7655 5384
% 27.8% 17.5% 13.1% 11.0% 11.1% 11.9% 12.3%
AJCC stage <0.001
I- II 326 1857 6736 15467 23031 29743 19712
% 27.6% 34.8% 36.0% 39.5% 43.0% 46.0% 44.9%
III -IV 705 2828 9432 17834 22753 25328 15786
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Table 1 Characteristics of patients from SEER database by age (Continued)
% 59.7% 53.0% 50.4% 45.6% 42.5% 39.2% 36.0%
Unknown 150 648 2559 5824 7756 9571 8384
% 12.7% 12.2% 13.7% 14.9% 14.5% 14.8% 19.1%
*Including American Indian/AK Native, Asian/Pacific Islander.
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OS rates, but they were better than those in the 80+ age
group, especially for OS. Second, in the non-operated
group, there was continued worsening in CCSS and OS
with increasing age, except for a slight increase in the
51–60 age group. The 5-year CCSS and OS rates de-
creased from 21.2% to 11.9% and from 18.2% to 4.3% in
the 15–30 compared with 80+ age group, respectively
(Table 2).
The results of the univariate survival analysis and mul-
tivariable Cox proportional hazard regression analysis ofTable 2 Long time survival rate (CSS/OS) in colorectal cancer
15-30 31-40 41-50 5
Total (n = 1181) (n = 5333) (n = 18727) (n
CSS
1-year CCS 84.6% 88.8% 88.8% 8
3-year CCS 66.4% 72.7% 73.3% 7
5-year CCS 58.5% 65.7% 66.3% 6
OS
1-year OS 83.5% 87.9% 87.8% 8
3-year OS 64.8% 71.0% 71.6% 7
5-year OS 56.6% 63.6% 63.5% 6
Operated group (n = 1073) (n = 4874) (n = 17025) (n
5-year CCS
1-year CCS 88.4% 91.7% 92.3% 9
3-year CCS 70.4% 76.5% 77.9% 7
5-year CCS 62.1% 69.6% 70.7% 7
OS
1-year OS 87.4% 90.9% 91.6% 9
3-year OS 69.1% 75.1% 76.3% 7
5-year OS 60.4% 67.6% 68.3% 6
Non-operated group (n = 98) (n = 416) (n = 1594) (n
CSS
1-year CCS 42.7% 55.6% 50.2% 5
3-year CCS 25.2% 27.2% 23.4% 2
5-year CCS 21.2% 20.3% 18.4% 1
OS
1-year OS 41.1% 54.0% 48.1% 4
3-year OS 21.6% 25.0% 21.8% 2
5-year OS 18.2% 18.0% 16.4% 1age and various covariates with respect to CCSS in oper-
ated and non-operated groups are shown in Tables 3, 4,
5 and 6, and Figures 1 and 2. In the operated group,
multivariable analysis demonstrated statistically signifi-
cant increases in HR after age 60. Patients in the 61–70
age group were 1.1 times more likely to die of cancer
than patients in the 51–60 age group. The risk was sig-
nificantly higher for the patients in the 71–80 age group
who were 1.3 times more likely to die of cancer than
those in the 51–60 age group. Finally, the risk was
higher still for patients in the 80+ age group who wereby age
1-60 61-70 71-80 >80 P value
= 39125) (n = 53540) (n = 64642) (n = 43882)
<0.001
8.7% 86.8% 82.8% 74.2%
5.1% 74.1% 70.4% 60.0%
8.0% 67.6% 64.0% 53.5%
7.2% 83.9% 77.3% 63.8%
2.4% 68.9% 60.5% 43.0%
4.0% 60.0% 49.9% 30.5%
= 35729) (n = 48909) (n = 58248) (n = 36890)
<0.001
2.1% 90.6% 87.3% 80.6%
9.5% 78.4% 75.2% 67.0%
2.3% 71.8% 68.6% 60.1%
0.8% 88.0% 82.3% 70.7%
6.8% 73.4% 65.5% 49.5%
8.3% 64.2% 54.2% 35.3%
= 3150) (n = 4318) (n = 6017) (n = 6647)
0.3% 43.0% 37.4% 36.5%
5.6% 23.3% 20.7% 17.0%
9.7% 18.3% 16.7% 11.9%
7.6% 38.7% 30.7% 26.3%
3.0% 19.2% 14.2% 8.4%
7.0% 14.0% 9.8% 4.3%
Table 3 Univariate survival analyses of CRC patients in


























African American 20149 61.6%
Others* 16580 72.4%
Pathological grading 812.382 <0.001
I- II 150521 72.0%
III-IV 38018 52.7%
Unknown 14209 77.2%
Histological Type 1162.165 <0.001
Adenocarcinoma 177748 70.0%
Mucinous/Signet ring cancer 25000 59.7%










*Including other (American Indian/AK Native, Asian/Pacific Islander) and
unknowns.
Table 4 Univariate survival analyses of CRC patients in non-


























African American 3218 12.2%
Others* 1772 23.9%
Pathological grading 812.382 <0.001
I- II 11275 19.9%
III-IV 3113 9.2%
Unknown 7852 14.4%
Histological Type 116.240 <0.001
Adenocarcinoma 20362 17.2%
Mucinous/Signet ring cancer 1878 9.3%






*Including other (American Indian/AK Native, Asian/Pacific Islander) and
unknowns.
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old patients. Patients in the elderly age groups (61–70,
71–80, and 80+) had significantly worse survival than
those in the 51–60 age group (P < 0.001), but the differ-
ence in survival between those in the 51–60 age group
compared with the other three younger age groups (15-
30, 31-40, 41-50) wasn’t statistically significant (P > 0.05)
Table 5 Multivariate Cox model analyses of prognostic
factors of CRC in operated group
Variable Hazard ratio 95%CI P







15-30 1.055 0.955-1.165 0.294
31-40 0.954 0.906-1.005 0.077
41-50 0.979 0.948-1.011 0.203
51-60 1.000 Reference
61-70 1.082 1.056-1.109 <0.001
71-80 1.325 1.294-1.356 <0.001
>80 1.951 1.902-2.002 <0.001
Pathological grading <0.001
I- II 1.000 Reference
III-IV 1.443 1.418-1.468 <0.001
Unknown 0.913 0.880-0.948 <0.001
Histological Type <0.001
Adenocarcinoma 1.000 Reference
Mucinous/Signet ring cancer 1.200 1.175-1.226
AJCC stage <0.001
I- II 1.000 Reference
III- IV 4.880 4.791-4.971 <0.001
Unknown 1.170 1.130-1.210 <0.001
No. of LNs dissected <0.001
<12 1.000 Reference
≥12 0.793 0.780-0.806 <0.001
Unknown 2.269 2.183-2.358 <0.001
Table 6 Multivariate Cox model analyses of prognostic
factors of CRC in non-operated group
Variable Hazard ratio 95%CI P










15-30 0.975 0.761-1.251 0.845
31-40 0.886 0.784-1.002 0.055
41-50 1.021 0.951-1.097 0.567
51-60 1.000 Reference
61-70 1.185 1.121-1.253 <0.001
71-80 1.463 1.388-1.543 <0.001
>80 1.859 1.762-1.961 <0.001
Race <0.001
Caucasian 1.000 Reference
African American 1.160 1.109-1.214 <0.001
Others* 0.871 0.818-0.927 <0.001
Pathological grading <0.001
I- II 1.000 Reference
III-IV 1.430 1.365-1.498 <0.001
Unknown 1.141 1.100-1.184 <0.001
Histological Type 0.001
Adenocarcinoma 1.000 Reference
Mucinous/Signet ring cancer 1.112 1.050-1.177
AJCC stage <0.001
I- II 1.000 Reference
III- IV 7.808 6.260-9.739 <0.001
Unknown 2.735 2.192-3.412 <0.001
*Including other (American Indian/AK Native, Asian/Pacific Islander) and
unknowns.
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hook-shaped curve and HRs sharply increased in the
above 60 age group (Table 5, Figure 3a).
In the non-operated groups, multivariable analysis
demonstrated similar results with the operated
group. The risk of death from CRC continued to in-
crease in the above 60 age group, such that patients
in the 61–70, 71–80 and 80+ age groups were 1.2,
1.5 and 1.9 times, respectively more likely to die of
cancer than patients in the 51–60 age group. Those
in the 15-30, 31-40, 41-50 age groups experienced
similar CCSS compared with those in the 51–60 age
group (P > 0.05) (Table 6). The curves of the HRs in
these groups was steadily constant until the age of
40, when the HR started to apparently increase with
increasing age (Table 6 and Figure 3b).Discussion
Conflicting results have been reported regarding
whether age affects the prognosis of CRC. In general,
it is assumed that young patients have a higher
prevalence of mucinous or poorly differentiated tu-
mors including signet ring carcinoma and later stage
and elderly patients have a higher percentage of co-
morbidities and emergency surgeries, all of which
means poorer prognosis compared with others.
Whether age itself is an independent survival factor
is unknown. Previous studies have demonstrated that
Figure 1 Survival curves according to each age subgroups in colorectal patients in operated group.
Figure 2 Survival curves according to each age subgroups in colorectal patients in non-operated group.
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Figure 3 Estimates of hazard ratios (HRs) of colorectal cancer-specific mortality changing with age for (a) operated and (b) non-operated
group using quintic polynomial regression. The solid blue lines represent the estimates of HRs, whereas the dotted orange lines represent the
95% confidence intervals. All R2 values are reported.
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example is well differentiated thyroid cancer for
which the American Joint Committee on Cancer
(AJCC) incorporates age into its staging criteria:
patients less than 45 years of age with well differenti-
ated thyroid cancer cannot be diagnosed with stage
III or IV disease [27].
In our study cohort, we found that patients in the 51–
60 age group had a relatively good prognosis, and the
difference with elderly age groups (61-70-, 71–80, 80+)
was statistically significant, but the difference between
the 51–60 and younger groups was not significant. This
result was validated in both operated and non-operated
age groups. Although young patients always had a higher
prevalence of later stage (stage III/IV) and mucinous,
signet-ring and poorly differentiated tumors which
tended to have a poorer prognosis compared with well
and moderately differentiated tumors [28], the surgical
resection rate and survival rate were comparable withother age groups in our study. What is interesting is that
if patients didn’t undergo surgical resection, the younger
they were, the better was the prognosis.
Generally, CRC is thought to be a malignancy affecting
mostly the elderly, with more than 90% of patients being
diagnosed after age 55, and our study indicated that it
seems reasonable to use 60 years as the cutoff between
young and elderly patients. We then conducted an analysis
comparing clinicopathological and survival analysis com-
paring groups of patients above and below 60 years of age,
Young patients with CRC aged 60 and below had unfavor-
able clinicopathological characteristics, but they still had a
higher CSS (χ2 = 631.268, P < 0.001). (Additional file 1:
Table S1 and Additional file 2: Figure S1).
In general, young patients always had a good perfor-
mance status, which is essential for the success of chemo-
therapy [29] and extensive lymphadenectomy. Clinicians
are more inclined to use all therapeutic options, such as
combination chemotherapy and surgery in young patients
Li et al. BMC Cancer  (2015) 15:83 Page 9 of 11than elderly ones because they are in better health and are
more likely to tolerate toxicities associated with chemother-
apy [10,30,31]. In a retrospective large multi-institutional
study, chemotherapy use in patients with stage III disease
decreased with increasing age, with patients >80 years
receiving adjuvant chemotherapy in only 25.6% of cases in
comparison with 82.4% of cases in patients <40. For select
patients with stage II disease, younger patients more fre-
quently received chemotherapy than older patients (69.2%
for those <40 year, 46.0% for those 40–50, 27.0% for those
50–80 and 5.6% for those >80 years of age), and similar
results were found in rectal cancer [32].
Increased adjuvant therapy use in younger patients
may partially account for stage-specific increases in
survival. Moreover, the sharp decline in the use of ad-
juvant therapy with increasing age could not be justi-
fied by the effect of comorbidities, treatment toxicity,
short natural life expectancies, and health care
[32,33]. In several institutional series, young patients
more often received regional or surgical therapy com-
pared with older patients [13,34,35]. Conversely, poor
tolerance to treatment due to poor performance sta-
tus or the presence of other comorbid medical condi-
tions may contribute to inferior survival of older
patients [12]. Chagpar et al. found that, among pa-
tients with stage III disease, older age was associated
with under treatment, independent of preexisting co-
morbidities, as well as other clinical pathologic and
socioeconomic factors [36].
When concerning metastatic CRC, several studies have
shown a significant improvement in survival when com-
paring patients managed with primary tumor resection to
those managed with chemotherapy alone [31,37-39], but
in fact elderly patients are less likely to receive palliative
surgery. Our data demonstrated that patients in the 80+
age group had an extremely low surgical resection rate
although they had relatively good clinicopathological char-
acteristics. Less aggressive treatment offered to patients
with limited comorbidities was likely to impact on their
outcome [40].
Young patients also have a higher proportion of tumors
demonstrating microsatellite instability, which are associ-
ated with a better prognosis [41]. Although survival of
patients with advanced CRC has significantly increased
in clinical trials incorporating new therapeutic agents
[42], a meta-analysis comparing younger and older pa-
tients with advanced CRC enrolled in randomized clinical
trials of newer chemotherapy agents between 1995 and
2004 demonstrated equal survival in both groups [43]. In
fact, patients enrolled in clinical trials are always strictly
selected and under thorough supervision. Our analysis of
the SEER data demonstrated that the younger the
patients were, the better their survival, even for patients
who received no surgical therapy.This study adds to current knowledge by answering
more in-depth research questions about age and progno-
sis through analysis large population-based data from
the SEER database, however, it had several potential lim-
itations. First, the SEER database only had limited infor-
mation on tumor factors, which could affect survival
analysis. Second, concerning treatment modalities, the
SEER definition of surgery does not separate treatment
with palliative intent from that with curative intent.
Thus, the beneficial effect of surgery on survival may be
underestimated, specifically for those patients who
underwent radical resection. Finally, the SEER database
does not include information on comorbidities which
limits our ability to calculate the impact of comorbid
conditions on CSS. Various studies on CRC surgery and
treatment outcomes show a progressive increase in post-
operative morbidity and mortality with advancing age
[44,45], which are likely to impact their short-term sur-
vival. Moreover, some studies have shown that postoper-
ative morbidity had a negative impact on long-term
outcomes following radical surgery of various tumors
[46-48]. Still, our study has sufficient power for a larger
population-based study.
Conclusions
In conclusion, our study demonstrated that in the operated
group, those aged 51–60 had the best prognosis, while in
the non-operated groups, those of very young age 15–30
had the best prognosis. Both CCS and OS continued to
decline with further advances in age after 60 as exemplified
by worsening survival in the >60 age group. Recognition of
these findings is important for clinicians who must consider
if age should be incorporated into their assessments and
treatment decisions for patients with CRC.
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